(2026). Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: Real-world experience with therapeutic drug monitoring. JAC-Antimicrobial Resistance.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Oritavancin as Consolidation or Suppressive Therapy in Infective Endocarditis and Device-related Infections: Real-world Experience with Therapeutic Drug Monitoring."
JAC-Antimicrobial Resistance 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Oritavancin as Consolidation or Suppressive Therapy in Infective Endocarditis and Device-related Infections: Real-world Experience with Therapeutic Drug Monitoring."
JAC-Antimicrobial Resistance, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.